What the low impact of Humira biosimilars teaches us about drug prices

Almost everyone seems to agree that drug prices are too high. But that agreement stops when it comes to the question of why they’re so high, and to the question of how to bring them down. 

Goodroot CEO Mike Waterbury and Nuwae Health CEO Ralph Pisano discuss how the community of Goodroot companies, including Nuwae, are attacking that issue from different angles.